相对于其它抗癌治疗，价格也反映了基因泰克公司对药品的感知价值。
The price also reflected Genentech's perceived value of the drug compared with other cancer treatments.
因此基因泰克公司开发了一种单克隆抗体，这种蛋白将绑定VEGF而使之失效。
So Genentech developed a monoclonal antibody, a type of protein, that would bind to VEGF and disable it.
六月份，雅培公司和基因泰克公司宣布，两公司将运用这种方法合作开发一种抗癌药。
In June, Abbott Laboratories Inc. and Genentech said they would collaborate to develop a cancer drug using this approach.
位于巴塞尔的罗氏公司自去年收购基因泰克公司之后成为了世界上最大的生物科技公司。
Roche, based in Basel, is the world’s largest biotech company and bought Genentech last year.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
但是一个不同寻常的利益冲突意味着制药公司基因泰克对此格外地沉默。
But an unusual conflict of interest means that Genentech, the drug company that produces Lucentis, is conspicuously silent.
十多年前就取得了重大进展，一个加州的生物科技公司Genentech(中文名：基因泰克)发行了一种药物，这种药物攻击蛋白质HER2(中文名：人表皮生长因子受体- 2)含量过多的乳腺癌细胞。
A breakthrough came more than a decade ago when Genentech, a Californian biotech firm, launched a drug that attacks breast-cancer cells with too much of a certain protein, HER2.
包括基因泰克和诺华制药在内的一些制药公司正在研究可以进入细胞内部并阻断VEGF的小分子抗癌药物。
But a number of drug companies including Genentech and Novartis AG are looking at small molecule cancer drugs that can get inside cells and block VEGF.
包括基因泰克和诺华制药在内的一些制药公司正在研究可以进入细胞内部并阻断VEGF的小分子抗癌药物。
But a number of drug companies including Genentech and Novartis AG are looking at small molecule cancer drugs that can get inside cells and block VEGF.
应用推荐